Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression
Sponsor: Navitor Pharmaceuticals, Inc.
Listed as NCT05066672, this observational or N/A phase trial focuses on Treatment Resistant Depression and remains completed. Sponsored by Navitor Pharmaceuticals, Inc., it has been updated 7 times since 2022, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Study Description(click to expand)The is a multicenter, randomized, double-blind, flexible- dose, placebo-controlled, parallel design of adjunctive NV-5138 in adults with TRD.
The is a multicenter, randomized, double-blind, flexible- dose, placebo-controlled, parallel design of adjunctive NV-5138 in adults with TRD.
Status Flow
Change History
7 versions recorded-
Apr 18, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Jun 2025 — Apr 2026 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Apr 2022 — Dec 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
Contact Information
- Navitor Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .